What is the current Stock Price of Kopran Ltd as on 28 February 2026?

The current stock price of Kopran Ltd as on 28 February 2026 is 132.

Kopran Ltd: Intrinsic Value & Share Price Analysis

Q: What is the intrinsic value of Kopran Ltd?

Kopran Ltd's intrinsic value (as of 28 February 2026) is 192.77 which is 46.04% higher than the current market price of 132.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 638 Cr. market cap, FY2025-2026 high/low of 215/120, reserves of ₹453 Cr, and liabilities of 813 Cr.

Q: What is the High / Low of Kopran Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Kopran Ltd stocks is 215/120.

Share Price and Basic Stock Data

Last Updated: February 27, 2026, 8:42 pm

Market Cap	638 Cr.
Current Price	132
Intrinsic Value	₹192.77
High / Low	215/120
Stock P/E	38.5
Book Value	104
Dividend Yield	2.28 %
ROCE	9.75 %
ROE	7.64 %
Face Value	10.0
PEG Ratio	-1.67

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Kopran Ltd

Competitors

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Kopran Ltd	638 Cr.	132	215/120	38.5	104	2.28 %	9.75 %	7.64 %	10.0
Kilitch Drugs (India) Ltd	556 Cr.	324	500/265	21.4	152	0.00 %	15.7 %	12.6 %	10.0
Anuh Pharma Ltd	776 Cr.	77.2	115/68.0	18.6	32.6	1.94 %	17.2 %	13.4 %	5.00
Themis Medicare Ltd	788 Cr.	85.8	179/75.2		41.3	0.58 %	10.4 %	7.65 %	1.00
Albert David Ltd	409 Cr.	712	959/663	42.5	690	0.70 %	6.45 %	4.39 %	10.0
Industry Average	20,545.80 Cr	1,097.97		55.88	201.21	0.37%	16.35%	15.16%	6.10

All Competitor Stocks of Kopran Ltd

Quarterly Result

Metric	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Sales	158.00	148.88	117.00	152.59	158.92	186.08	139.44	151.56	166.24	172.36	135.22	117.91	194.28
Expenses	145.68	136.72	110.69	129.76	135.34	164.39	121.28	136.83	146.39	155.27	121.09	123.19	176.52
Operating Profit	12.32	12.16	6.31	22.83	23.58	21.69	18.16	14.73	19.85	17.09	14.13	-5.28	17.76
OPM %	7.80%	8.17%	5.39%	14.96%	14.84%	11.66%	13.02%	9.72%	11.94%	9.92%	10.45%	-4.48%	9.14%
Other Income	2.22	3.78	2.39	0.13	2.43	9.67	2.63	1.00	0.17	3.26	2.56	0.03	0.07
Interest	2.24	1.78	1.83	1.94	2.24	2.59	2.18	2.23	2.16	2.77	2.54	2.09	2.67
Depreciation	3.16	3.24	3.26	2.77	3.27	3.59	3.87	3.85	4.00	3.87	4.26	4.28	4.42
Profit before tax	9.14	10.92	3.61	18.25	20.50	25.18	14.74	9.65	13.86	13.71	9.89	-11.62	10.74
Tax %	23.96%	26.37%	22.99%	24.55%	23.02%	26.01%	24.69%	23.42%	24.96%	29.39%	24.67%	-14.63%	13.04%
Net Profit	6.95	8.04	2.77	13.77	15.79	18.62	11.10	7.38	10.40	9.68	7.45	-9.92	9.34
EPS in Rs	1.44	1.67	0.57	2.86	3.28	3.86	2.30	1.53	2.16	2.01	1.54	-2.06	1.94

Last Updated: February 5, 2026, 6:16 am

Below is a detailed analysis of the quarterly data for Kopran Ltd based on the most recent figures (Dec 2025) and their trends compared to the previous period:

For Sales, as of Dec 2025, the value is 194.28 Cr.. The value appears strong and on an upward trend. It has increased from 117.91 Cr. (Sep 2025) to 194.28 Cr., marking an increase of 76.37 Cr..
For Expenses, as of Dec 2025, the value is 176.52 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 123.19 Cr. (Sep 2025) to 176.52 Cr., marking an increase of 53.33 Cr..
For Operating Profit, as of Dec 2025, the value is 17.76 Cr.. The value appears strong and on an upward trend. It has increased from -5.28 Cr. (Sep 2025) to 17.76 Cr., marking an increase of 23.04 Cr..
For OPM %, as of Dec 2025, the value is 9.14%. The value appears strong and on an upward trend. It has increased from -4.48% (Sep 2025) to 9.14%, marking an increase of 13.62%.
For Other Income, as of Dec 2025, the value is 0.07 Cr.. The value appears strong and on an upward trend. It has increased from 0.03 Cr. (Sep 2025) to 0.07 Cr., marking an increase of 0.04 Cr..
For Interest, as of Dec 2025, the value is 2.67 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.09 Cr. (Sep 2025) to 2.67 Cr., marking an increase of 0.58 Cr..
For Depreciation, as of Dec 2025, the value is 4.42 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4.28 Cr. (Sep 2025) to 4.42 Cr., marking an increase of 0.14 Cr..
For Profit before tax, as of Dec 2025, the value is 10.74 Cr.. The value appears strong and on an upward trend. It has increased from -11.62 Cr. (Sep 2025) to 10.74 Cr., marking an increase of 22.36 Cr..
For Tax %, as of Dec 2025, the value is 13.04%. The value appears to be increasing, which may not be favorable. It has increased from -14.63% (Sep 2025) to 13.04%, marking an increase of 27.67%.
For Net Profit, as of Dec 2025, the value is 9.34 Cr.. The value appears strong and on an upward trend. It has increased from -9.92 Cr. (Sep 2025) to 9.34 Cr., marking an increase of 19.26 Cr..
For EPS in Rs, as of Dec 2025, the value is 1.94. The value appears strong and on an upward trend. It has increased from -2.06 (Sep 2025) to 1.94, marking an increase of 4.00.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 24, 2026, 7:16 pm

Metric	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	303	326	296	310	313	358	360	492	478	551	615	630	620
Expenses	260	294	266	274	283	312	313	410	390	499	540	557	576
Operating Profit	43	31	30	36	31	46	47	82	87	52	74	73	44
OPM %	14%	10%	10%	12%	10%	13%	13%	17%	18%	9%	12%	12%	7%
Other Income	2	-48	1	11	9	3	-0	18	11	3	15	4	6
Interest	14	13	13	14	9	9	9	6	5	6	9	9	10
Depreciation	13	10	8	8	9	9	10	10	11	13	13	16	17
Profit before tax	17	-39	11	25	23	32	28	83	82	36	68	52	23
Tax %	0%	0%	0%	20%	10%	24%	26%	26%	25%	24%	25%	26%
Net Profit	17	-39	11	20	20	24	21	62	61	27	51	39	17
EPS in Rs	4.40	-9.52	2.48	4.60	4.74	5.55	4.86	14.24	12.66	5.65	10.57	7.99	3.43
Dividend Payout %	0%	0%	0%	0%	0%	0%	0%	21%	24%	53%	28%	38%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024	2024-2025
YoY Net Profit Growth (%)	-329.41%	128.21%	81.82%	0.00%	20.00%	-12.50%	195.24%	-1.61%	-55.74%	88.89%	-23.53%
Change in YoY Net Profit Growth (%)	0.00%	457.62%	-46.39%	-81.82%	20.00%	-32.50%	207.74%	-196.85%	-54.12%	144.63%	-112.42%

Kopran Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:	7%
5 Years:	12%
3 Years:	10%
TTM:	-2%

Compounded Profit Growth
10 Years:	10%
5 Years:	12%
3 Years:	-14%
TTM:	-41%

Stock Price CAGR
10 Years:	14%
5 Years:	18%
3 Years:	-2%
1 Year:	-51%

Return on Equity
10 Years:	13%
5 Years:	12%
3 Years:	8%
Last Year:	8%

Last Updated: September 5, 2025, 9:15 am

Balance Sheet

Last Updated: December 4, 2025, 1:32 am

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Sep 2025
Equity Capital	39	41	43	43	43	43	43	43	48	48	48	48	48
Reserves	67	49	57	81	101	125	146	202	378	391	443	470	453
Borrowings	137	86	80	95	89	97	88	66	75	75	99	148	157
Other Liabilities	56	99	84	78	82	85	92	128	110	135	153	178	155
Total Liabilities	299	275	264	298	315	351	370	439	611	650	743	844	813
Fixed Assets	105	102	101	104	104	113	111	112	151	165	182	208	235
CWIP	20	1	3	6	10	24	30	43	36	70	97	113	114
Investments	1	0	0	0	0	0	0	0	0	0	0	0	0
Other Assets	174	172	160	187	201	214	229	284	425	415	465	522	465
Total Assets	299	275	264	298	315	351	370	439	611	650	743	844	813

Below is a detailed analysis of the balance sheet data for Kopran Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

For Equity Capital, as of Sep 2025, the value is 48.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 48.00 Cr..
For Reserves, as of Sep 2025, the value is 453.00 Cr.. The value appears to be declining and may need further review. It has decreased from 470.00 Cr. (Mar 2025) to 453.00 Cr., marking a decrease of 17.00 Cr..
For Borrowings, as of Sep 2025, the value is 157.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 148.00 Cr. (Mar 2025) to 157.00 Cr., marking an increase of 9.00 Cr..
For Other Liabilities, as of Sep 2025, the value is 155.00 Cr.. The value appears to be improving (decreasing). It has decreased from 178.00 Cr. (Mar 2025) to 155.00 Cr., marking a decrease of 23.00 Cr..
For Total Liabilities, as of Sep 2025, the value is 813.00 Cr.. The value appears to be improving (decreasing). It has decreased from 844.00 Cr. (Mar 2025) to 813.00 Cr., marking a decrease of 31.00 Cr..
For Fixed Assets, as of Sep 2025, the value is 235.00 Cr.. The value appears strong and on an upward trend. It has increased from 208.00 Cr. (Mar 2025) to 235.00 Cr., marking an increase of 27.00 Cr..
For CWIP, as of Sep 2025, the value is 114.00 Cr.. The value appears strong and on an upward trend. It has increased from 113.00 Cr. (Mar 2025) to 114.00 Cr., marking an increase of 1.00 Cr..
For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
For Other Assets, as of Sep 2025, the value is 465.00 Cr.. The value appears to be declining and may need further review. It has decreased from 522.00 Cr. (Mar 2025) to 465.00 Cr., marking a decrease of 57.00 Cr..
For Total Assets, as of Sep 2025, the value is 813.00 Cr.. The value appears to be declining and may need further review. It has decreased from 844.00 Cr. (Mar 2025) to 813.00 Cr., marking a decrease of 31.00 Cr..

Notably, the Reserves (453.00 Cr.) exceed the Borrowings (157.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity +	3	46	29	16	26	25	31	60	-33	34	43	42
Cash from Investing Activity +	-9	-10	-9	-18	-11	-25	-13	-25	-84	-13	-44	-56
Cash from Financing Activity +	7	-37	-19	2	-15	-1	-18	-35	123	-20	1	26
Net Cash Flow	0	-0	0	-0	-0	-0	0	0	5	2	1	11

Free Cash Flow

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Free Cash Flow	-94.00	-55.00	-50.00	-59.00	-58.00	-51.00	-41.00	16.00	12.00	-23.00	-25.00	-75.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days	68	91	70	86	75	88	94	89	97	108	126	125
Inventory Days	103	78	119	122	138	129	154	121	202	133	126	153
Days Payable	69	119	115	95	118	90	95	104	84	89	103	108
Cash Conversion Cycle	101	50	74	113	96	127	153	106	215	152	149	170
Working Capital Days	45	9	34	43	60	70	79	81	158	139	131	113
ROCE %	14%	14%	14%	19%	14%	16%	14%	30%	21%	8%	14%	10%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Promoters	44.29%	44.49%	44.49%	44.49%	44.49%	44.49%	44.49%	44.45%	44.42%	44.43%	44.43%	44.43%
FIIs	0.41%	0.34%	0.39%	0.48%	0.84%	0.68%	1.31%	0.86%	1.11%	0.76%	0.60%	0.36%
DIIs	0.14%	0.14%	0.35%	0.14%	1.20%	0.14%	0.22%	0.00%	0.00%	0.00%	0.00%	0.00%
Public	55.15%	55.03%	54.78%	54.88%	53.47%	54.68%	53.98%	54.68%	54.45%	54.81%	54.99%	55.21%
No. of Shareholders	41,567	44,038	53,791	51,636	50,850	51,492	57,154	60,560	58,652	60,194	62,222	60,886

Shareholding Pattern Chart

No. of Shareholders

Kopran Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund Name	No of Shares	AUM (%)	Amount Invested (Cr)	Previous Number of Shares	Previous Date	Percentage Change
Quant Healthcare Fund	101,067	1.41	2.28	101,067	2025-04-22 17:25:28	0%
Motilal Oswal S&P BSE Healthcare ETF	251	0.07	0.01	251	2025-04-22 17:25:28	0%

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21
FaceValue	10.00	10.00	10.00	10.00	10.00
Basic EPS (Rs.)	7.99	10.57	5.65	13.77	14.24
Diluted EPS (Rs.)	7.99	10.57	5.65	13.77	14.24
Cash EPS (Rs.)	11.21	13.24	8.29	14.96	16.60
Book Value[Excl.RevalReserv]/Share (Rs.)	107.35	101.90	91.11	88.40	56.65
Book Value[Incl.RevalReserv]/Share (Rs.)	107.35	101.90	91.11	88.40	56.65
Revenue From Operations / Share (Rs.)	130.39	127.48	114.29	99.05	113.71
PBDIT / Share (Rs.)	15.92	18.47	11.38	20.33	23.07
PBIT / Share (Rs.)	12.69	15.79	8.74	18.02	20.71
PBT / Share (Rs.)	10.76	14.01	7.48	16.96	19.27
Net Profit / Share (Rs.)	7.98	10.57	5.65	12.66	14.24
NP After MI And SOA / Share (Rs.)	7.98	10.57	5.65	12.66	14.24
PBDIT Margin (%)	12.21	14.48	9.95	20.52	20.28
PBIT Margin (%)	9.73	12.38	7.64	18.19	18.21
PBT Margin (%)	8.25	10.99	6.54	17.12	16.94
Net Profit Margin (%)	6.12	8.29	4.94	12.78	12.52
NP After MI And SOA Margin (%)	6.12	8.29	4.94	12.78	12.52
Return on Networth / Equity (%)	7.43	10.37	6.19	14.32	25.14
Return on Capital Employeed (%)	11.04	14.51	8.91	18.91	32.14
Return On Assets (%)	4.56	6.85	4.19	9.99	14.02
Long Term Debt / Equity (X)	0.03	0.03	0.04	0.04	0.08
Total Debt / Equity (X)	0.28	0.20	0.17	0.17	0.26
Asset Turnover Ratio (%)	0.79	0.88	0.87	0.45	0.64
Current Ratio (X)	1.76	2.08	2.25	2.74	1.72
Quick Ratio (X)	1.18	1.44	1.52	1.75	1.10
Inventory Turnover Ratio (X)	4.09	2.93	2.29	1.82	1.81
Dividend Payout Ratio (NP) (%)	37.51	28.38	53.10	10.62	10.53
Dividend Payout Ratio (CP) (%)	26.71	22.65	36.20	8.99	9.03
Earning Retention Ratio (%)	62.49	71.62	46.90	89.38	89.47
Cash Earning Retention Ratio (%)	73.29	77.35	63.80	91.01	90.97
Interest Coverage Ratio (X)	8.23	10.36	9.02	19.15	15.99
Interest Coverage Ratio (Post Tax) (X)	5.13	6.93	5.48	12.93	10.87
Enterprise Value (Cr.)	967.40	1330.79	595.14	1372.72	511.32
EV / Net Operating Revenue (X)	1.54	2.17	1.08	2.87	1.04
EV / EBITDA (X)	12.58	14.95	10.85	14.01	5.13
MarketCap / Net Operating Revenue (X)	1.34	2.03	0.96	2.84	0.92
Retention Ratios (%)	62.48	71.61	46.89	89.37	89.46
Price / BV (X)	1.63	2.54	1.21	3.19	1.85
Price / Net Operating Revenue (X)	1.34	2.03	0.96	2.84	0.92
EarningsYield	0.04	0.04	0.05	0.04	0.13

After reviewing the key financial ratios for Kopran Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
For Basic EPS (Rs.), as of Mar 25, the value is 7.99. This value is within the healthy range. It has decreased from 10.57 (Mar 24) to 7.99, marking a decrease of 2.58.
For Diluted EPS (Rs.), as of Mar 25, the value is 7.99. This value is within the healthy range. It has decreased from 10.57 (Mar 24) to 7.99, marking a decrease of 2.58.
For Cash EPS (Rs.), as of Mar 25, the value is 11.21. This value is within the healthy range. It has decreased from 13.24 (Mar 24) to 11.21, marking a decrease of 2.03.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 107.35. It has increased from 101.90 (Mar 24) to 107.35, marking an increase of 5.45.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 107.35. It has increased from 101.90 (Mar 24) to 107.35, marking an increase of 5.45.
For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 130.39. It has increased from 127.48 (Mar 24) to 130.39, marking an increase of 2.91.
For PBDIT / Share (Rs.), as of Mar 25, the value is 15.92. This value is within the healthy range. It has decreased from 18.47 (Mar 24) to 15.92, marking a decrease of 2.55.
For PBIT / Share (Rs.), as of Mar 25, the value is 12.69. This value is within the healthy range. It has decreased from 15.79 (Mar 24) to 12.69, marking a decrease of 3.10.
For PBT / Share (Rs.), as of Mar 25, the value is 10.76. This value is within the healthy range. It has decreased from 14.01 (Mar 24) to 10.76, marking a decrease of 3.25.
For Net Profit / Share (Rs.), as of Mar 25, the value is 7.98. This value is within the healthy range. It has decreased from 10.57 (Mar 24) to 7.98, marking a decrease of 2.59.
For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 7.98. This value is within the healthy range. It has decreased from 10.57 (Mar 24) to 7.98, marking a decrease of 2.59.
For PBDIT Margin (%), as of Mar 25, the value is 12.21. This value is within the healthy range. It has decreased from 14.48 (Mar 24) to 12.21, marking a decrease of 2.27.
For PBIT Margin (%), as of Mar 25, the value is 9.73. This value is below the healthy minimum of 10. It has decreased from 12.38 (Mar 24) to 9.73, marking a decrease of 2.65.
For PBT Margin (%), as of Mar 25, the value is 8.25. This value is below the healthy minimum of 10. It has decreased from 10.99 (Mar 24) to 8.25, marking a decrease of 2.74.
For Net Profit Margin (%), as of Mar 25, the value is 6.12. This value is within the healthy range. It has decreased from 8.29 (Mar 24) to 6.12, marking a decrease of 2.17.
For NP After MI And SOA Margin (%), as of Mar 25, the value is 6.12. This value is below the healthy minimum of 8. It has decreased from 8.29 (Mar 24) to 6.12, marking a decrease of 2.17.
For Return on Networth / Equity (%), as of Mar 25, the value is 7.43. This value is below the healthy minimum of 15. It has decreased from 10.37 (Mar 24) to 7.43, marking a decrease of 2.94.
For Return on Capital Employeed (%), as of Mar 25, the value is 11.04. This value is within the healthy range. It has decreased from 14.51 (Mar 24) to 11.04, marking a decrease of 3.47.
For Return On Assets (%), as of Mar 25, the value is 4.56. This value is below the healthy minimum of 5. It has decreased from 6.85 (Mar 24) to 4.56, marking a decrease of 2.29.
For Long Term Debt / Equity (X), as of Mar 25, the value is 0.03. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.03.
For Total Debt / Equity (X), as of Mar 25, the value is 0.28. This value is within the healthy range. It has increased from 0.20 (Mar 24) to 0.28, marking an increase of 0.08.
For Asset Turnover Ratio (%), as of Mar 25, the value is 0.79. It has decreased from 0.88 (Mar 24) to 0.79, marking a decrease of 0.09.
For Current Ratio (X), as of Mar 25, the value is 1.76. This value is within the healthy range. It has decreased from 2.08 (Mar 24) to 1.76, marking a decrease of 0.32.
For Quick Ratio (X), as of Mar 25, the value is 1.18. This value is within the healthy range. It has decreased from 1.44 (Mar 24) to 1.18, marking a decrease of 0.26.
For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.09. This value is within the healthy range. It has increased from 2.93 (Mar 24) to 4.09, marking an increase of 1.16.
For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 37.51. This value is within the healthy range. It has increased from 28.38 (Mar 24) to 37.51, marking an increase of 9.13.
For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 26.71. This value is within the healthy range. It has increased from 22.65 (Mar 24) to 26.71, marking an increase of 4.06.
For Earning Retention Ratio (%), as of Mar 25, the value is 62.49. This value is within the healthy range. It has decreased from 71.62 (Mar 24) to 62.49, marking a decrease of 9.13.
For Cash Earning Retention Ratio (%), as of Mar 25, the value is 73.29. This value exceeds the healthy maximum of 70. It has decreased from 77.35 (Mar 24) to 73.29, marking a decrease of 4.06.
For Interest Coverage Ratio (X), as of Mar 25, the value is 8.23. This value is within the healthy range. It has decreased from 10.36 (Mar 24) to 8.23, marking a decrease of 2.13.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 5.13. This value is within the healthy range. It has decreased from 6.93 (Mar 24) to 5.13, marking a decrease of 1.80.
For Enterprise Value (Cr.), as of Mar 25, the value is 967.40. It has decreased from 1,330.79 (Mar 24) to 967.40, marking a decrease of 363.39.
For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.54. This value is within the healthy range. It has decreased from 2.17 (Mar 24) to 1.54, marking a decrease of 0.63.
For EV / EBITDA (X), as of Mar 25, the value is 12.58. This value is within the healthy range. It has decreased from 14.95 (Mar 24) to 12.58, marking a decrease of 2.37.
For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.34. This value is within the healthy range. It has decreased from 2.03 (Mar 24) to 1.34, marking a decrease of 0.69.
For Retention Ratios (%), as of Mar 25, the value is 62.48. This value is within the healthy range. It has decreased from 71.61 (Mar 24) to 62.48, marking a decrease of 9.13.
For Price / BV (X), as of Mar 25, the value is 1.63. This value is within the healthy range. It has decreased from 2.54 (Mar 24) to 1.63, marking a decrease of 0.91.
For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.34. This value is within the healthy range. It has decreased from 2.03 (Mar 24) to 1.34, marking a decrease of 0.69.
For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.04.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Kopran Ltd as of February 28, 2026 is: ₹250.30

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of February 28, 2026, Kopran Ltd is Undervalued by 89.62% compared to the current share price ₹132.00

Intrinsic Value of Kopran Ltd as of February 28, 2026 is: ₹192.77

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of February 28, 2026, Kopran Ltd is Undervalued by 46.04% compared to the current share price ₹132.00

Last 5 Year EPS CAGR: -22.99%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The stock has a high average ROCE of 15.67%, which is a positive sign. The company has higher reserves (227.92 cr) compared to borrowings (99.38 cr), indicating strong financial stability. The company has shown consistent growth in sales (434.77 cr) and profit (33.92 cr) over the years.	The stock has a high average Working Capital Days of 80.17, which may not be favorable. The stock has a high average Cash Conversion Cycle of 125.50, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Kopran Ltd:
1. Net Profit Margin: 6.12%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 11.04% (Industry Average ROCE: 16.35%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 7.43% (Industry Average ROE: 15.16%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 5.13
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 1.18
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 38.5 (Industry average Stock P/E: 55.88)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.28
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Kopran Ltd. is a Public Limited Listed company incorporated on 26/04/1958 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24230MH1958PLC011078 and registration number is 011078. Currently Company is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company's Total Operating Revenue is Rs. 271.01 Cr. and Equity Capital is Rs. 48.29 Cr. for the Year ended 31/03/2025.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	Parijat House, 1076, Dr. E. Moses Road, Mumbai Maharashtra 400018	Contact not found

Management
Name	Position Held
Mr. Susheel G Somani	Chairman
Mr. Surendra Somani	Executive Vice Chairman
Mr. Adarsh Somani	Director
Mr. Varun Somani	Director
Dr. Siddhan Subramanian	Independent Director
Dr. Sunita Banerji	Independent Director
Mrs. Mamta Biyani	Independent Director
Mr. Narayan Atal	Independent Director

FAQ

What is the intrinsic value of Kopran Ltd?

Kopran Ltd's intrinsic value (as of 27 February 2026) is ₹192.77 which is 46.04% higher the current market price of ₹132.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹638 Cr. market cap, FY2025-2026 high/low of ₹215/120, reserves of ₹453 Cr, and liabilities of ₹813 Cr.

What is the Market Cap of Kopran Ltd?

The Market Cap of Kopran Ltd is 638 Cr..

What is the current Stock Price of Kopran Ltd as on 27 February 2026?

The current stock price of Kopran Ltd as on 27 February 2026 is ₹132.

What is the High / Low of Kopran Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Kopran Ltd stocks is ₹215/120.

What is the Stock P/E of Kopran Ltd?

The Stock P/E of Kopran Ltd is 38.5.

What is the Book Value of Kopran Ltd?

The Book Value of Kopran Ltd is 104.

What is the Dividend Yield of Kopran Ltd?

The Dividend Yield of Kopran Ltd is 2.28 %.

What is the ROCE of Kopran Ltd?

The ROCE of Kopran Ltd is 9.75 %.

What is the ROE of Kopran Ltd?

The ROE of Kopran Ltd is 7.64 %.

What is the Face Value of Kopran Ltd?

The Face Value of Kopran Ltd is 10.0.